Effect of Aqueous Extract of Azadirachta indica Leaves on Pharmacokineics and Pharmacodynamics of Glipizide
| Autor: | Sugandha Chaudhari, Shitalkumar Zambad, Mohammed Ali |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Blood Glucose
Male Clinical Biochemistry Cmax Herb-Drug Interactions Pharmaceutical Science Pharmacology Diet High-Fat Streptozocin Diabetes Mellitus Experimental Rats Sprague-Dawley 03 medical and health sciences 0302 clinical medicine Pharmacokinetics medicine Animals Cytochrome P-450 CYP3A Humans Hypoglycemic Agents Pharmacology (medical) Glucose tolerance test Azadirachta biology medicine.diagnostic_test Chemistry Plant Extracts Biochemistry (medical) biology.organism_classification Streptozotocin Bioavailability Rats Plant Leaves Diabetes Mellitus Type 2 030220 oncology & carcinogenesis Pharmacodynamics Area Under Curve Polypharmacy 030217 neurology & neurosurgery Glipizide medicine.drug |
| Zdroj: | Drug metabolism letters. 13(1) |
| ISSN: | 1874-0758 |
| Popis: | Background: Polypharmacy, that is, two (or more) drugs administered together, may cause chemical or pharmacological interactions. Such interactions may alter the effect of either agent, leading to decrease or increase effectiveness of the drugs, which may cause adverse effects. The co-intake of complementary and alternative medicines with therapeutic medicine are supposed to influence pharmacodynamics or pharmacokinetics of the latter. Objective: This study was conducted to determine the interaction of glipizide (GZ) with an aqueous extract of Azadirachta indica (AZI) leaves. Method: The pharmacokinetics and pharmacodynamics of glipizide was evaluated in High Fat diet (HFD) and streptozotocin induced diabetic Sprague-Dawley rats. Two doses of the AZI leaf extract (250 and 500 mg/kg) were administered alone or in combination with GZ (5 mg/kg) and serum glucose during oral glucose tolerance test, AST, ALT, and ALP levels were as estimated. In vitro CYP3A activity of AZI at 50 µg and 100 µg was assessed using liver microsomes. Results: In the glucose tolerance test, AZI and GZ showed a hypoglycemic effect. However, the hypoglycemic effect was lower when AZI was administered in combination with GZ compared with GZ alone. AZI at 100 µg has shown significant potentiation of CYP3A activity. AZI (500 mg/kg) pretreatment significantly decreased AUC and increased Tmax to 8 h. Conclusion: This indicated that the pharmacokinetics and pharmacodynamics of GZ altered by AZI might be due to the induction of CYP3A activity. In conclusion, AZI can decrease the bioavailability of GZ, and hence, it should be cautiously used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|